Research Cluster
Cardiovascular & Vascular Peptides
Cardiovascular peptide therapeutics represent one of the most clinically mature application areas in the field. Four of the seven compounds in this cluster are FDA-approved drugs with Phase III data, established clinical protocols, and decades of real-world use. This is not a research-stage cluster—it is an active therapeutic area where peptide drugs are standard of care in interventional cardiology and heart failure management.
The three crossover compounds—SS-31, VIP, and oxytocin—add a research and emerging-application dimension to a cluster otherwise dominated by approved therapeutics. Understanding what the approved compounds do, and how they differ mechanistically from the research-stage ones, is the interpretive work this page does.
Cluster at a Glance
7 compounds • 4 FDA-approved • 1 Phase II clinical program • 2 pilot/limited human data • Highest clinical maturity cluster on the site
Approved Drug
Clinical Trials
Pilot / Human Data
Editorial note: The approved compounds in this cluster are prescription-only cardiovascular drugs used in acute and hospital settings. They are documented here as part of the peptide therapeutics landscape—not as compounds relevant to self-experimentation or research use outside clinical care. The crossover compounds (SS-31, VIP, oxytocin) are the research-stage portion of this cluster.
How These Compounds Relate
The approved compounds in this cluster operate across three distinct cardiovascular mechanisms. Eptifibatide and bivalirudin are anticoagulation and antiplatelet agents targeting the coagulation cascade during acute coronary events—one blocks platelet aggregation at the GP IIb/IIIa receptor, the other blocks thrombin directly. Nesiritide addresses cardiac preload and afterload via natriuretic peptide receptor signaling. CGRP antagonists target neurogenic vascular tone and migraine pathophysiology via the most potent known vasodilatory peptide system. These are pharmacologically distinct mechanisms that happen to converge on cardiovascular outcomes.
Eptifibatide and bivalirudin share an acute procedural setting—both are IV-only drugs used in the catheterization laboratory during PCI—but target different points in the coagulation process. Eptifibatide prevents platelet plug formation. Bivalirudin prevents fibrin clot formation. Their co-use in some protocols reflects this mechanistic complementarity, though current evidence favors one or the other depending on the clinical context rather than routine combination.
CGRP occupies a unique position: the endogenous peptide is a cardiovascular regulator with well-characterized effects on vascular tone and coronary physiology, but the approved drugs are anti-CGRP agents for migraine rather than cardiovascular therapeutics. The migraine-cardiovascular connection is real—CGRP is central to both—but the approved indications are neurological, not cardiac.
SS-31, VIP, and oxytocin represent the research frontier of this cluster. SS-31 is the most clinically advanced of the three, with Phase II data specifically in heart failure. VIP’s PAH program represents the most directly cardiovascular application of a compound that does most of its work in immune and injury contexts. Oxytocin’s cardiac biology is the least developed of the three—a scientifically credible emerging area without yet a clinical program specifically for cardiovascular indications.